2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
“[When we look at the 2-year data], 54.4% of patients were alive after treatment with glofitamab plus GemOx compared with only 33.6% of patients treated with rituximab [Rituxan] plus GemOx. We also observed benefits in terms of secondary efficacy end points…. [These data at 2 years] show that the benefits [with glofitamab plus GemOx] are [both] deep and durable, with substantial improvements in complete response rate, progression-free survival, and overall survival favoring glofitamab plus GemOx over rituximab plus GemOx; this benefit is durable.”
Jeremy Abramson, MD, director of the Lymphoma Program at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School, discussed the significance of the 2-year follow-up findings from the phase 3 STARGLO trial (NCT04408638) evaluating glofitamab (Columvi) in combination with gemcitabine and oxaliplatin (GemOx) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous stem cell transplant (ASCT).
The trial demonstrated sustained efficacy of the fixed-duration glofitamab/GemOx regimen (n = 183), with 54.4% (95% CI, 46.8%-62.0%) of patients alive at 24 months. Among those who achieved a complete response at end of treatment (EOT), 89.3% (95% CI, 82.3%-96.4%) remained alive 12 months after treatment cessation.
Additionally, among all patients who received glofitamab plus GemOx, the median progression-free survival was 13.8 months (95% CI, 8.8-30.0), and 46.5% (95% CI, 38.5%-54.5%) of patients remained progression free at 18 months, underscoring the durability of the regimen, according to Abramson.
Immune recovery was observed between 18 and 24 months after EOT, providing reassurance regarding the long-term immunologic safety of this regimen in this transplant-ineligible population. The overall safety profile remained consistent with known toxicities associated with glofitamab and the chemotherapy backbone, and no new safety concerns emerged during extended follow-up.
According to Abramson, glofitamab plus GemOx represents a viable off-the-shelf, fixed-duration treatment option for patients with relapsed/refractory DLBCL who are not candidates for ASCT or CAR T-cell therapy. He noted that the regimen offers meaningful disease control and may help patients avoid the need for ongoing therapy, which is particularly relevant in a population often characterized by poor performance status and limited therapeutic alternatives.
Related Content: